Table 2.
Sarcopenia quantification with group comparison and Spearman correlation coefficients by PhA in the BaSAlt cohort
| SARC-F (in points) Md (range) mean ± SD | MHF (in kg) Md (range) mean ± SD | ASMM (in kg) Md (range) mean ± SD | 4MWS (in m/s) Md (range) mean ± SD | |
|---|---|---|---|---|
|
No sarcopenia ngroup = 32 nfemale = 25, nmale = 7 |
3.0 (0–9) 3.17 ± 2.83 |
18.0 (16–40) 20.50 ± 5.99 |
16.3 (11.5–25.7) 17.37 ± 3.31 |
0.63 (0.27–0.95) 0.61 ± 0.19 |
|
Probable sarcopenia ngroup = 33 nfemale = 21, nmale = 12 |
3.0 (0–10) 3.36 ± 2.81 |
14.0 (2–26) 14.91 ± 6.44 |
19.7 (15.0–31.4) 20.11 ± 4.29 |
0.59 (0.32–1.02) 0.60 ± 0.18 |
|
Confirmed/ severe sarcopenia ngroup = 13 nfemale = 12, nmale = 1 |
4.5 (0–7) 4.10 ± 2.38 |
12.0 (0–26) 11.38 ± 6.12 |
13.2 (8.4–18.1) 12.97 ± 2.61 |
0.49 (0.28–0.90) 0.55 ± 0.18 |
| Kruskal–Wallis-Test | H = 1.372, p = 0.504 | H = 25.991, p < 0.001* | H = 27.085, p < 0.001* | H = 0.966, p = 0.617 |
| Dunn–Bonferroni-post-hoc-tests | ||||
| No sarcopenia–probable sarcopenia | – | z = 3.672, p = 0.001* | z = − 2.484, p = 0.039* | – |
| No sarcopenia–confirmed/ severe sarcopenia | – | z = 1.943, p = 0.156 | z = 3.273, p = 0.003* | – |
| Probable sarcopenia–confirmed/ severe sarcopenia | – | z = 4.706, p < 0.001* | z = 5.170, p < 0.001* | – |
| Spearman correlation with PhA | r = − 0.106, p = 0.392 | r = 0.111, p = 0.338 | r = 0.477, p < 0.001* | r = − 0.001, p = 0.994 |
Essential is the indication of the p-values in italics, which are additionally marked as significant with a *
*Significant result for p ≤ 0.05 (two-sided test)